Background
Methods
Korean breast cancer registry
Study population
Statistical analysis
Results
Patients’ characteristics and distribution based on molecular subtype
IDC group (n = 14,547) | ILC group (n = 528) | P-value | |
---|---|---|---|
Age | |||
Mean ± SD | 48.5 ± 10.3 | 48.9 ± 9.3 | 0.297 |
Median (range) | 47.0 (19.0 to 93.0) | 47.0 (24.0 to 82.0) | 0.321 |
<50 | 8736 (60.1) | 323 (61.2) | 0.109 |
50≤ | 5811 (39.9) | 205 (38.8) | |
Tumor size | |||
Mean ± SD | 2.3 ± 1.4 | 2.9 ± 1.9 | <0.001 |
Median (range) | 2.0 (0.1 to 16.0) | 2.5 (0.3 to 14.0) | <0.001 |
T ≤ 2 cm | 7,556 (51.9) | 218 (41.3) | <0.001 |
2 cm < T ≤ 5 cm | 6,341 (43.6) | 251 (47.5) | |
5 cm < T | 650 (5.2) | 59 (11.2) | |
Nodal status | |||
0 | 8238 (56.6) | 289 (54.7) | 0.248 |
1 to 3 | 4067 (28.0) | 141 (26.7) | |
4 to 9 | 1481 (10.2) | 67 (12.7) | |
10≤ | 761 (5.2) | 31 (5.9) | |
TNMstage | |||
stage I | 5323 (36.6) | 166 (31.4) | 0.001 |
stage II | 6819 (46.9) | 244 (46.2) | |
stage III | 2405 (16.5) | 118 (22.4) | |
Lymphatic invasion | |||
no | 9,337 (64.2) | 343 (65.0) | 0.714 |
yes | 5,210 (35.8) | 185 (35.0) | |
Vascular invasion | |||
no | 11,794 (81.1) | 387 (73.3) | <0.001 |
yes | 2,753 (18.9) | 141 (26.7) | |
Estrogen receptor status | |||
negative | 5,698 (39.2) | 103 (19.5) | <0.001 |
positive | 8,849 (60.8) | 425 (80.5) | |
Progesterone receptor status | |||
negative | 6,370 (43.8) | 134 (25.4) | <0.001 |
positive | 8,177 (56.2) | 394 (74.6) | |
HER2 | |||
negative | 11,381 (78.2) | 496 (93.9) | <0.001 |
positive | 3,166 (21.8) | 32 (6.1) | |
Radiation therapy | |||
no | 6,570 (45.2) | 265 (50.2) | 0.023 |
yes | 7,977 (54.8) | 263 (49.8) | |
Chemotherapy | |||
no | 2,499 (17.2) | 96 (18.2) | 0.549 |
yes | 12,048 (82.8) | 432 (81.8) | |
Hormonal therapy | |||
no | 4,549 (31.3) | 81 (15.3) | <0.001 |
yes | 9,998 (68.7) | 447 (84.7) | |
Surgery | |||
mastectomy | 8,112 (55.8) | 354 (67.1) | <0.001 |
breast conserving surgery | 6,435 (44.2) | 174 (32.9) | |
Molecular subtype | |||
luminal A | 8,196 (56.3) | 439 (83.2) | <0.001 |
luminal B | 1,638 (11.3) | 25 (4.7) | |
HER2-overexpression | 1,528 (10.5) | 7 (1.3) | |
Triple negative | 3,185 (21.9) | 57 (10.8) |
Breast cancer-specific survival and overall survival of the IDC and ILC patients
Effect of molecular subtype on the breast cancer-specific survival and overall survival of IDC and ILC patients
Multivariate analysis for prognostic factors
IDC (n = 14,547) | ||||
---|---|---|---|---|
BCSSHR (95% CI) | P-value | OS HR (95% CI) | P-value | |
Age | ||||
<50 | 1 | 1 | ||
50≤ | 1.060 (0.929 to 1210) | 0.386 | 1.067 (0.944 to 1.206) | 0.302 |
Surgery | ||||
mastectomy | 1 | 1 | ||
breast conserving surgery | 1.049 (0.937 to 1.175) | 0.405 | 1.08 (0.906 to 1.121) | 0.882 |
Tumor size | ||||
T ≤ 2 cm | 1 | 1 | ||
2 cm < T ≤ 5 cm | 1.228 (1.101 to 1.369) | <0.001 | 1.233 (1.112 to 1.366) | <0.001 |
5 cm < T | 1.434 (1.218 to 1.689) | <0.001 | 1.395 (1.192 to 1.632) | <0.001 |
Nodal status | ||||
0 | 1 | 1 | ||
1 to 3 | 1.045 (0.919 to 1.189) | 0.501 | 1.043 (0.926 to 1.174) | 0.488 |
4 to 9 | 0.940 (0.679 to 1.302) | 0.710 | 0.903 (0.662 to 1.233) | 0.522 |
10≤ | 1.018 (0.734 to 1.412) | 0.916 | 0.951 (0.695 to 1.30) | 0752 |
TNMstage | ||||
stage I | 1 | 1 | ||
stage II | 1.090 (0.949 to 1.253) | 0.223 | 1.018 (0.897 to 1.155) | 0.784 |
stage III | 1.563 (1.344 to 1.818) | <0.001 | 1.392 (1.211 to 1.601) | <0.001 |
Molecular subtype | ||||
luminal A | 1 | 1 | ||
luminal B | 1.175 (1.022 to 1.350) | 0.023 | 1.182 (1.039 to 1.344) | 0.011 |
HER2-overexpression | 1.426 (1.200 to 1.695) | <0.001 | 1.406 (1.201 to 1.646) | <0.001 |
Triple negative | 2.523 (2.160 to 2.948) | <0.001 | 2.219 (1.924 to 2.559) | <0.001 |
Lymphatic invasion | ||||
no | 1 | 1 | ||
yes | 4.206 (3.748 to 4.721) | <0.001 | 3.212 (2.899 to 3.559) | <0.001 |
Vascular invasion | ||||
no | 1 | 1 | ||
yes | 3.019 (2.747 to 3.317) | <0.001 | 2.777 (2.540 to 3.036) | <0.001 |
Estrogen receptor status | ||||
negative | 1 | 1 | ||
positive | 0.736 (0.633 to 0.857) | <0.001 | 0.671 (0.585 to 0.771) | <0.001 |
Progesterone receptor status | ||||
negative | 1 | 1 | ||
positive | 0.960 (0.826 to 1.117) | 0.600 | 0.993 (0.861 to 1.146) | 0.928 |
HER2 | ||||
negative | 1 | 1 | ||
positive | 1.426 (1.200 to 1.695) | <0.001 | 1.401 (1.197 to 1.640) | <0.001 |
Radiation therapy | ||||
no | 1 | 1 | ||
yes | 1.012 (0.911 to 1.124) | 0.826 | 1.010 (0.915 to 1.116) | 0.841 |
Chemotherapy | ||||
no | 1 | 1 | ||
yes | 1.059 (0.895 to 1.252) | 0.506 | 1.113 (0.958 to 1.295) | 0.162 |
Hormonal therapy | ||||
no | 1 | 1 | ||
yes | 1.025 (0.914 to 1.149) | 0.671 | 1.007 (0.905 to 1.121) | 0.894 |
ILC (n = 528) | ||||
---|---|---|---|---|
BCSS HR (95% CI) | P-value | OS HR (95% CI) | P-value | |
Age | ||||
<50 | 1 | 1 | ||
50≤ | 0.898 (0.424 to 1.904) | 0.780 | 0.708 (0.350 to 1.435) | 0.338 |
Surgery | ||||
mastectomy | 1 | 1 | ||
breast conserving surgery | 1.059 (0.520 to 2.157) | 0.874 | 1.224 (0.645 to 2.324) | 0.536 |
Tumor size | ||||
T ≤ 2 cm | 1 | 1 | ||
2 cm < T ≤ 5 cm | 0.524 (0.205 to 1.337) | 0.176 | 0.507 (0.215 to 1.196) | 0.121 |
5 cm < T | 0.275 (0.055 to 1.367) | 0.114 | 0.343 (0.077 to 1.527) | 0.160 |
Nodal status | ||||
0 | 1 | 1 | ||
1 to 3 | 0.156 (0.216 to 1.232) | 0.136 | 0.525 (0.244 to 1.128) | 0.099 |
4 to 9 | 0.307 (0.074 to 1.267) | 0.103 | 0.335 (0.090 to 1.250) | 0.104 |
10≤ | 0.441 (0.103 to 1.886) | 0.270 | 0.449 (0.116 to 1.737) | 0.246 |
TNMstage | ||||
stage I | 1 | 1 | ||
stage II | 1.271 (0.634 to 2.548) | 0.500 | 1.409 (0.753 to 2.639) | 0.284 |
stage III | 4.242 (2.023 to 8.897) | <0.001 | 3.647 (1.826 to 7.285) | <0.001 |
Molecular subtype | ||||
luminal A | 1 | 1 | ||
luminal B | 2.117 (0.903 to 4.961) | 0.084 | 2.157 (0.977 to 4.764) | 0.057 |
HER2-overexpression | 1.499 (0.349 to 6.434) | 0.586 | 1.769 (0.344 to 9.106) | 0.495 |
Triple negative | 3.543 (2.078 to 6.042) | <0.001 | 3.977 (1.653 to 9.565) | 0.002 |
Lymphatic invasion | ||||
no | 1 | 1 | ||
yes | 0.732 (0.389 to 1.375) | 0.332 | 0.802 (0.455 to 1.415) | 0.446 |
Vascular invasion | ||||
no | 1 | 1 | ||
yes | 1.260 (0.690 to 0.299) | 0.452 | 1.068 (0.608 to 1.875) | 0.819 |
Estrogen receptor status | ||||
negative | 1 | 1 | ||
positive | 1.649 (0.464 to 5.859) | 0.439 | 1.657 (0.482 to 5.697) | 0.423 |
Progesterone receptor status | ||||
negative | 1 | 1 | ||
positive | 0.546 (0.277 to 1.076) | 0.080 | 0.568 (0.318 to 1.014) | 0.056 |
HER2 | ||||
negative | 1 | 1 | ||
positive | 3.591 (0.353 to 36.498) | 0.280 | 3.644 (0.395 to 33.657) | 0.254 |
Radiation therapy | ||||
no | 1 | 1 | ||
yes | 0.844 (0.463 to 1.537) | 0.579 | 0.795 (0.456 to 1.387) | 0.419 |
Chemotherapy | ||||
no | 1 | 1 | ||
yes | 1.178 (0.466 to 2.977) | 0.730 | 1.011 (0.453 to 2.259) | 0.979 |
Hormonal therapy | ||||
no | 1 | 1 | ||
yes | 2.063 (0.826 to 5.153) | 0.121 | 2.112 (0.952 to 4.688) | 0.066 |